S&P 500
7,226.20
+0.01%
Dow Jones
49,494.60
-0.62%
Nasdaq 100
27,685.40
+0.66%
Russell 2000
2,804.78
-0.02%
FTSE 100
10,364.50
0.00%
Nikkei 225
59,260.50
-0.78%

Health and Healthcare

Savient (SVNT) Rises 55% On Bad News

Photo of Douglas A. McIntyre
By Douglas A. McIntyre Updated Published
Follow 24/7 Wall St. on Google
This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.

bearShares in pharma firm Savient (SVNT) are up 55% to $9.13 on what would appear to be very bad news. The FDA issued a statement saying it has safety concerns about the company’s gout drug.

According to the agency, side effects of the drug Krystexxa include sudden death from heart attack and allergic reactions. The silver lining is that the treatment may actually be approved. The FDA commented that it does “does not dispute the efficacy” of the drug.

Reuters reports that“Savient, in a separate document also released on Friday, said the drug was important for patients who have no other options and that it “can be successfully managed with careful clinical monitoring.”

Apparently patient heart attacks are good for the company’s shareholders.

Douglas A. McIntyre

Photo of Douglas A. McIntyre
About the Author Douglas A. McIntyre →

Douglas A. McIntyre is the co-founder, chief executive officer and editor in chief of 24/7 Wall St. and 24/7 Tempo. He has held these jobs since 2006.

McIntyre has written thousands of articles for 24/7 Wall St. He is an expert on corporate finance, the automotive industry, media companies and international finance. He has edited articles on national demographics, sports, personal income and travel.

His work has been quoted or mentioned in The New York Times, The Wall Street Journal, Los Angeles Times, The Washington Post, NBC News, Time, The New Yorker, HuffPost USA Today, Business Insider, Yahoo, AOL, MarketWatch, The Atlantic, Bloomberg, New York Post, Chicago Tribune, Forbes, The Guardian and many other major publications. McIntyre has been a guest on CNBC, the BBC and television and radio stations across the country.

A magna cum laude graduate of Harvard College, McIntyre also was president of The Harvard Advocate. Founded in 1866, the Advocate is the oldest college publication in the United States.

TheStreet.com, Comps.com and Edgar Online are some of the public companies for which McIntyre served on the board of directors. He was a Vicinity Corporation board member when the company was sold to Microsoft in 2002. He served on the audit committees of some of these companies.

McIntyre has been the CEO of FutureSource, a provider of trading terminals and news to commodities and futures traders. He was president of Switchboard, the online phone directory company. He served as chairman and CEO of On2 Technologies, the video compression company that provided video compression software for Adobe’s Flash. Google bought On2 in 2009.

Featured Reads

Our top personal finance-related articles today. Your wallet will thank you later.

How Much Do You Really Need in Treasury Bonds to Replace a $50,000 Salary With Interest
Drew Wood |

How Much Do You Really Need in Treasury Bonds to Replace a $50,000 Salary With Interest
Fed’s Rate Freeze Could Sting for Social Security Recipients
Maurie Backman |

Fed’s Rate Freeze Could Sting for Social Security Recipients

Continue Reading

Douglas A. McIntyre |

Shares of Savient Pharmaceuticals Inc. Soar Despite FDA Concern Over Drug Safety (SVNT)

Shares of Savient Pharmaceuticals Inc. (Nasdaq: SVNT) climbed on Friday after an announcement by the FDA that the company’s drug…
Douglas A. McIntyre |

Savient: Jim Cramer’s Old Favorite Biotech Implodes (SVNT)

Savient Pharmaceuticals Inc. (NASDAQ: SVNT) is feeling the wrath of the trading gods today.  Shares are down some 74% at…
Douglas A. McIntyre |

Boston Scientific (BSX): The Stent Business Can’t Get More Confused

After reports last week that drug-coated stents posed little risk to heart patients, a new survey shows that  "patients given…
Douglas A. McIntyre |

Stent Safety Issues at the FDA….Hogwash

Stock Tickers: BSX, JNJ, ANPI, SRDX, CONR, BMY, SNY, ABT, MDT The FDA review of stents should not change the…
Douglas A. McIntyre |

GlaxoSmithKline Continues Down A Dangerous Path

Two more studies show that GlaxoSmithKline (GSK) blockbuster diabetes drug Avandia has significant health risks. According to The Wall Street…
Will New Marketing Push Pump Amarin Stock?
247sarah |

Will New Marketing Push Pump Amarin Stock?

Amarin is going ahead with a big marketing campaign for potential COVID treatment Vascepa after a disruption caused by the…
Douglas A. McIntyre |

Glaxo: Why Does The News Come So Late?

GlaxoSmithKline (GSK) has come out with a ton of information that say its diabetes drug  Avandia is safe for the…
Douglas A. McIntyre |

Merck’s Next Horse Pill (MRK)(WMT)

Like most of the Big Pharma companies, Merck needs a winner. Wall St. is scared witless that generic drug firms…
Douglas A. McIntyre |

Anti-Smoking Drugs Could Cause Suicide (PFE)(GSK)

It is hard to say whether a person is better off stopping smoking and lessening their chances of a heart…

Top Gaining Stocks

Cboe Global Markets
CBOE • Vol: 1,568,143
New Pluto Global
PSKY • Vol: 12,285,993
Seagate Technology
STX • Vol: 7,378,346
Oracle
ORCL • Vol: 26,317,675
Datadog
DDOG • Vol: 6,247,779

Top Losing Stocks

LKQ
LKQ • Vol: 4,367,433
Clorox
CLX • Vol: 13,260,523
Stryker
SYK • Vol: 4,519,455
Mohawk Industries
MHK • Vol: 1,859,865
Amgen
AMGN • Vol: 3,818,618